1330633-99-2

Basic information

• Product Name: (E)-2'',2''-difluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid
• CAS NO: 1330633-99-2
• Molecular Weight: 487.478
• Mol File: 1330633-99-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-2'',2''-difluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2'',2''-difluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid(1330633-99-2)
• EPA Substance Registry System: (E)-2'',2''-difluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid(1330633-99-2)

Safety Data

• Hazardous Substances Data: 1330633-99-2(Hazardous Substances Data)

Upstream product

• 22216-44-0 2-(4-methoxy-3-nitrobenzylthio)acetic acid 
• 592542-51-3 4-methoxy-3-nitrophenylmethanesulfonyl acetic acid 
• 592542-50-2 (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline 
• 908344-08-1 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-aminobenzyl sulfide 
• 908344-21-8 3-nitro-4-methoxybenzyl mercaptan 
• 1330633-86-7 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-nitrobenzyl sulfide 
• 830-79-5 2,4,6-trimethoxybenzaldehyde 
• 136612-71-0 (2,4,6-Trimethoxyphenyl)acetylene 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 41870-24-0 (4-methoxy-3-nitrophenyl)methanol 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 1330633-90-3 (E)-methyl 2'',2''-difluoro-2(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetate 
• 1330633-87-8 2-(2’,2’-dibromovinyl)-1,3,5-trimethoxybenzene 

Relevant articles and documents

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.